KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Short term Debt (2016 - 2026)

Amgen has reported Short term Debt over the past 15 years, most recently at $5.4 billion for Q1 2026.

  • For Q1 2026, Short term Debt rose 61.43% year-over-year to $5.4 billion; the TTM value through Mar 2026 reached $5.4 billion, up 61.43%, while the annual FY2025 figure was $4.6 billion, 29.55% up from the prior year.
  • Short term Debt for Q1 2026 was $5.4 billion at Amgen, up from $4.6 billion in the prior quarter.
  • Over five years, Short term Debt peaked at $5.5 billion in Q2 2024 and troughed at $817.0 million in Q2 2022.
  • A 5-year average of $2.7 billion and a median of $2.2 billion in 2023 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 1728.74% in 2022 and fell as far as 81.11% in 2022.
  • Year by year, Short term Debt stood at $1.6 billion in 2022, then dropped by 9.3% to $1.4 billion in 2023, then surged by 146.02% to $3.6 billion in 2024, then grew by 29.55% to $4.6 billion in 2025, then increased by 18.22% to $5.4 billion in 2026.
  • Business Quant data shows Short term Debt for AMGN at $5.4 billion in Q1 2026, $4.6 billion in Q4 2025, and $2.2 billion in Q3 2025.